Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings

NCT04399551 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT04399551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04399551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
September 28, 2020
Completion date
March 13, 2023
Enrollment
437 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections